Form 4: Ginkgo Bioworks Director Granted 25,000 RSUs

Ginkgo Bioworks Director Christian O. Henry received a grant of 25,000 Restricted Stock Units as part of the company's non-employee director compensation program.

Summary

• Christian O. Henry, a Director at Ginkgo Bioworks Holdings, Inc. (DNA), was granted 25,000 Restricted Stock Units (RSUs).
• The transaction date for this grant was June 11, 2026.
• Each RSU represents a contingent right to receive one share of the Issuer's Class A Common Stock.
• The RSUs will vest on the earlier of June 11, 2027, or the day immediately prior to the date of the next Annual Meeting occurring after the grant date.
• Vesting is subject to Mr. Henry continuing in service as a Non-Employee Director through the vesting date.
• This grant was made in accordance with the Issuer's Amended and Restated Non-Employee Director Compensation Program, which became effective on June 11, 2026.
• Following this transaction, Mr. Henry beneficially owns 25,000 derivative securities (RSUs) directly.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this as a slightly positive development, as it represents a routine compensation event that aligns the director's financial interests with the long-term performance of the company and its shareholders.

Positives

• The grant of Restricted Stock Units to a non-employee director aligns management's long-term interests with those of shareholders, promoting a focus on sustained company performance.
• The equity-based compensation is a standard practice in corporate governance, indicating a structured approach to director remuneration.

Future Outlook

The future outlook indicates that the granted Restricted Stock Units are expected to vest, contingent upon the director's continued service, aligning his incentives with the company's long-term performance through at least June 2027.

Industry Context

StockSavvy.ai notes that providing equity compensation, such as Restricted Stock Units, to non-employee directors is a common and widely accepted practice across various industries, particularly in the biotechnology and technology sectors. This approach is designed to align the interests of directors with those of long-term shareholders, fostering a commitment to sustainable growth and value creation.

Comparison to Industry Standards

• The grant of Restricted Stock Units as part of a non-employee director compensation program is a standard practice consistent with global benchmarks for corporate governance and executive/director remuneration.
• While specific comparable companies or projects are not detailed in the filing, this type of equity-based compensation is prevalent among publicly traded companies, including peers in the synthetic biology and biotech space, to attract and retain qualified board members and incentivize long-term performance.

Corporate Governance

Stakeholder Impact

• Shareholders: The equity grant aligns the director's incentives with shareholder value creation, potentially leading to more focused long-term strategic decisions.
• Employees: No direct impact mentioned, but a well-compensated and aligned board can contribute to overall company stability and success.

Next Steps

• The Restricted Stock Units will vest on the earlier of June 11, 2027, or the day immediately prior to the date of the next Annual Meeting occurring after the grant date, subject to continued service.

Key Dates

Keywords

Ginkgo Bioworks, DNA, Restricted Stock Units, RSU, Director Compensation, Insider Transaction, Equity Grant, Form 4